Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | GPR6 | P46095 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080986 | 0.93 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4GPR6CYP11B2 | |
| SCHEMBL3073915 | 0.93 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP11B2HCRTR1 | |
| SCHEMBL3073530 | 0.90 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4CYP11B2HCRTR1 | |
| SCHEMBL3071510 | 0.88 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4CYP11B2TDO2 | |
| SCHEMBL3076011 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP11B2TDO2 | |
| SCHEMBL3078153 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4CYP11B2HCRTR1 | |
| SCHEMBL3081340 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4BACE1 | |
| SCHEMBL3087447 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4BACE1 | |
| SCHEMBL3076446 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4CYP11B2HCRTR1 | |
| SCHEMBL3077920 | 0.85 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-2146720-A1 | ARYLOXY-AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008141082-A1 | ARYLOXY-AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, HTR2B, ADRA1B | SLC6A2 10/4885SLC6A3 13/4885SLC6A4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.